ALEXANDRIA, Va., Feb. 19, 2025 /PRNewswire/ — SNA International is proud to announce the release of DNAConnect 2.0, the latest version of its industry-leading forensic DNA data management platform. Building on the success of DNAConnect 1.0, this version delivers expanded functionality and compliance capabilities to meet the demands of Rapid DNA for program directors, forensic laboratories, and law enforcement agencies worldwide.
With the FBI’s anticipated support for Rapid DNA use in casework, forensic laboratories and law enforcement agencies require solutions that streamline compliance with accreditation standards. DNAConnect 2.0 aligns with the latest FBI Quality Assurance Standards (QAS) while enhancing forensic oversight, security, and operational efficiency. The release coincides with the American Academy of Forensic Sciences (AAFS) Conference in Baltimore, where SNA International will showcase DNAConnect’s latest advancements.
“DNAConnect’s latest upgrade represents a pivotal advancement in forensic technology, ensuring laboratories can confidently expand their Rapid DNA programs supporting FBI QAS Section 19 compliance,” said Dr. Amanda Sozer, Founder and Chief Science Officer of SNA International. “As more agencies adopt Rapid DNA for casework, we remain focused on delivering solutions that uphold the highest forensic standards while empowering law enforcement to act quickly under laboratory oversight.”
Key Features of DNAConnect 2.0:
For more information, visit www.sna-intl.com.
SOURCE SNA International
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…